Advances in synthetic peptide immuno-regulatory epitopes

World Allergy Organization Journal

Volumn 7, Issue 1, 2014, Pages

  Creticos, Peter Socrates ^a,b  

^a Creticos Research Group   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN E; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLACEBO; SYNTHETIC PEPTIDE; SYNTHETIC PEPTIDE IMMUNO REGULATORY EPITOPE; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ALLERGY; ANTIGEN PRESENTING CELL; ARTHRALGIA; BRONCHOSPASM; CONVULSION; COUGHING; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; HYPERSENSITIVITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOTHERAPY; LIMB PAIN; NONHUMAN; NOSE OBSTRUCTION; PRESYNCOPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT DISEASE; REVIEW; RHINOCONJUNCTIVITIS; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SUBCUTANEOUS IMMUNOTHERAPY; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; UPREGULATION;

EID: 84988965981     PISSN: None     EISSN: 19394551     Source Type: Journal    
DOI: 10.1186/1939-4551-7-30     Document Type: Review

References (33)

1. Creticos PS: Immunotherapy with allergens. JAMA 1992, 268:2834-2839.
2. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, Nelson M, Weber R, Berstein DI, Blessing-Moore J, Khan DA, Lang DM, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph C, Schuller DE, Spector SL, Tilles S, Wallace D: Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011, 127(1 Suppl):S1-S55.
3. Creticos PS: Legends in Allergy: Philip S. Norman and Lawrence M. Lichtenstein-The Hopkins Experience. J Allergy Clin Immunol 2007, 11:1031-1038.
4. Shamji MH, Durham SR: Mechanisms of immunotherapy to aeroallergens. Clin Exp Allergy 2011, 41:1235-1246.
5. Broide DH: Immunomodulation of allergic disease. Annu Rev Med 2009, 60:279-291.
6. Valenta R, Ferreira F, Focke-Tejkl M, Linhart B, Niederberger V, Swoboda I, Vrtala S: From allergen genes to vaccines. Annu Rev Immunol 2010, 28:211-241.
7. Focke M, Swoboda I, Marth K, Valenta R: Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy 2010, 40:385-397.
8. Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Powanker R, Potter PC: Sublingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009, 64(Suppl 91):1-59.
9. Creticos PS: Sublingual immunotherapy for allergic rhinitis. In UpToDate. Edited by Post TW. Waltham, MA: UpToDate; (Accessed on Sept 15, 2014).
10. Briner TJ, Kuo M-C, Keating KM, Rogers BL: Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci U S A 1993, 90:7608-7612.
11. Wallner BP, Gefter ML: Immunotherapy with T-cell reactive peptides derived from allergens. Allergy 1994, 49:302-308.
12. Norman PS, Ohman JL Jr, Long AA, Creticos PS, Gefter MA, Shaked Z, Wood RA, Eggleston PA, Hafner KB, Rao P, Lichtenstein LM, Jones NH, Nicodemus CF: Treatment of cat allergy with T cell epitope containing peptides. Am J Respir Crit Care Med 1996, 154:1623-1628.
13. Norman PS, Nicodemus CF, Creticos PS, Wood RA, Eggleston PA, Lichtenstein LM, Kagey-Sobotka A, Proud D: Clinical and immunologic effects of component peptides in Allervax® Cat. Int Arch Allergy Immunol 1997, 113:1-3.
14. Creticos PS, Hebert J, Philip G, and the Allervax® Ragweed Study Group: Efficacy of Allervax® ragweed in the treatment of ragweed-induced allergy. J Allergy Clin Immunol 1997, 99, No. 1, Part 2:S401(1631).
15. Creticos PS: In Peptide Downregulation of the Immune Response. Asthma and Allergic Diseases. Edited by Marone G, Frank Austen K, Holgate ST, Barry Kay A, Lichtenstein LM. San Diego, CA: Harcourt Brace & Company Publishers. Academic Press; 1998:407-415. Chapter 30.
16. Smith T, Alexander C, Kay AB, Larche M, Robinson DS: Cat allergen peptide immunotherapy reduces CD4 T cell responses to cat allergen but does not alter suppression by CD4 CD25 T cells: a double-blind placebocontrolled study. Allergy 2004, 59:1097-1101.
17. Verhoef A, Alexander C, Kay AB, Larche M: T cell epitope immunotherapy induces a CD4(+) T cell population with regulatory activity. PLoS Med 2005, 2:e78.
18. Larche M: Immunotherapy with Allergen Peptides. Allergy Asthma Clin Immunol 2007, 3:53-59.
19. Campbell JD, Buckland KF, McMillan SJ, Kearley J, Oldfield W, Stern LJ, Gronlund H, van Hage M, Reynolds C, Boyton RJ, Cobbold SP, Kay AB, Altmann DM, Lloyd CM, Larche M: Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009, 206:1535.
20. Larche M, Moldavar D: Immunotherapy with Peptides. Allergy 2011, 66:784-791.
21. Worm M, Lee HH, Kleine-Tebbe J, Hafner RP, Laidler P, Healey D, Buhot C, Verhoef A, Maillere B, Kay AB, Larche M: Development and preliminary evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011, 127:89-97.
22. Oldfield W, Larche M, Kay AB: Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002, 360:47-53.
23. Worm M, Patel D, Creticos PS: Cat Peptide Antigen Desensitisation for Treating Cat Allergic Rhinoconjunctivitis. Expert Opin Investig Drugs 2013, 22:1347-1357.
24. Patel D, Couroux P, Hickey P, Salapatek AM, Laidler P, Larche M, Hafner R: Fel d 1-derived Peptide Antigen Desensitization Shows a Persistent Treatment Effect 1 Year After the Start of Dosing: a Randomized, Placebo-controlled Study. J Allergy Clin Immunol 2013, 131:103-109.
25. Hafner R, Couroux P, Armstrong K, Patel D, Larche M: Two Year Persistent Treatment Effect Achieved After 4 Doses of Cat-Peptide Antigen Desensitization in an EEC Model of Cat Allergy. J Allergy Clin Immunol 2013, 131:AB147.
26. Salapatek AM, Patel P, Chan K, Talwar N, von Weikersthal-Drachenberg KF, Amersdorffer J: An environmental exposure chamber-specific rhinoconjunctivitis quality of life questionnaire: the symptoms of seasonal allergic rhinitis correlate with the quality of life of patients with ragweed allergy in the chamber. Allergy 2007, 62:118-119.
27. Larche M, Patel D, Patel P, Salapatek A, Laidler P, Hafner R: Safety and Efficacy of Fel d 1-derived Peptide Immunotherapy in a DBPC Environmental Exposure Chamber Study. Allergy 2012, 67(Supp96):1-97.
28. Hafner R, Patel P, Salapatek A, Laidler P, Larche M, Patel D: Fel d 1 Peptide Antigen Desensitization Safety and Efficacy in a DBPC EEC Study. World Allergy Organ J 2013, 6(Supp):150.
29. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT: Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341:468-475.
30. Hafner R, Couroux P, Armstrong K, Patel D, Larche M, Haumann B: Two-year persistent treatment effect in reducing nasal symptoms of cat allergy after 4 doses of Cat-PAD, the first in a new class of synthetic peptide immun0-regulatory epitopes. Clin Transl Allergy 2013, 3(Suppl2):O7.
31. Circassia Ltd: A double-blind, randomized, placebo-controlled, multi-centre field study to assess the efficacy and safety of cat-PAD peptide immunotherapy in cat allergic subjects. In ClinicalTrials.gov [Internet]. Edited by Nelson H. Bethesda (MD): National Library of Medicine (US); 2000. (cited 2012 May 30). Available from: [http://clinicaltrials.gov/show/NCT01620762] NLM Identifier: NCT01620762.
32. Hafner RP, Salapatek A, Patel D, Larche M, Laidler P: Validation of Peptide Immunotherapy as a New Approach in the Treatment of Allergic Rhinoconjunctivitis: The clinical benefits of treatment with Amb a 1-derived Tcell epitopes. J Allergy Clin Immunol 2012, AB368.
33. Larche M, Hickey P, Hebert J, Hafner R: Safety and tolerability of escalating doses of HDM-peptide antigen desensitization. J Allergy Clin Immunol 2013, AB37.